• Synthetic biology developer ZKXY Bio raised a “hundreds of millions of yuan” private financing round advised by CEC Capital Group.
• Round led by an undisclosed strategic investor; Haiyuan Capital, Longgang Guidance Fund participated.
• Proceeds earmarked for building a synthetic biology platform, advancing multi-host strain development, accelerating industrialization, scaling biomanufacturing.
• Company combines AI with biotech; it is commercializing ingredients for personal care, nutrition supplements, flavor and fragrance markets.
• ZKXY is developing a filamentous-fungi chassis to expand non-food-feedstock biomanufacturing into larger-volume biobased products.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CEC Capital Group published the original content used to generate this news brief on July 31, 2026, and is solely responsible for the information contained therein.